Kweder: new law slows down FDA approvals

Share this article:
While it holds exciting promise for protecting public health, last year's FDA Amendments Act (FDAAA) is actually slowing down new drug approvals, a key agency official warned in June.

FDA Office of New Drugs Deputy director Sandra Kweder cautioned the Drug Information Association's annual meeting in Boston that this legislation is exceedingly complex and, at least in its initial application, is likely to result in delays by FDA in carrying out its individual provisions.

Under the FDAAA, Kweder said, “to assure conformance with provisions of Title IX, every NDA and BLA is a ‘first' so far as the agency is concerned,” she told the Drug Information Association annual meeting in Boston. “Everything we do must be justified, and every letter must be reviewed by the lawyers.”

She pointed out that every application must be considered on a case-by-case basis to determine which provisions apply, and which do not—for example, whether to require sponsors to produce a risk evaluation and mitigation strategy to accompany particular products.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Features

The Women's Health landscape is ripe with opportunity for pharma marketers. This seven-page eBook offers product managers a guide to capitalizing on the trends, growth areas and unmet needs. Includes alternative channels to engage OB/GYNs and oncologists, and plenty of tips. Click here to access it.

Email Newsletters